结直肠癌术后患者应用奥沙利铂联合卡培他滨方案化疗对外周血淋巴细胞亚群的影响

目的 观察ⅡB期～ⅢC期结直肠癌术后患者应用奥沙利铂联合卡培他滨方案化疗前后外周血淋巴细胞亚群水平变化,探讨奥沙利铂联合卡培他滨方案化疗对外周血淋巴细胞亚群的影响.方法 ⅡB～ⅢC期结直肠癌术后患者62例为结直肠癌组,体检健康者84例为对照组.结直肠癌患者术后给予奥沙利铂130 mg/m2,静脉滴注,2 h滴注完毕,第...

Influence of oxaliplatin plus capecitabine chemotherapy on peripheral blood lymphocyte subsets in postoperative patients with colorectal cancer

Objective To observe the changes of peripheral blood lymphocyte subsets before and after oxaliplatin plus capecitabine chemotherapy in postoperative stageⅡb andⅢC colorectal cancer patients,and to explore the influence of oxaliplatin plus capecitabine regimen on peripheral blood lymphocyte subsets.Methods Sixty-two patients with stageⅡB and stageⅢC colorectal cancer after operation were enrolled in colorectal cancer group,and another 84healthy volunteers were as controls(control group).Colorectal cancer group was given oxaliplatin 130mg/m2 intravenously within 2hon the first day,and capecitabine 1000mg/m2 orally twice a day on the first to 14th days,for 21days as a cycle,which was terminated till severe adverse reaction or disease progression.The peripheral blood samples were collected from colorectal cancer group one day before the first,third and fifth cycles of chemotherapy,and from control group on the day of physical examination.The percentage of lymphocyte subsets in peripheral blood was measured by flow cytometry and was compared one day before the first cycle of chemotherapy between two groups and among one day before the first,third and fifth cycles of chemotherapy in colorectal cancer group.Results In colorectal cancer group,the percentage of CD3⁺CD4⁺T cells((41.12±8.07)%),ratio of CD3⁺CD4⁺/CD3⁺CD8⁺T cells(1.57±0.61),percentage of CD19⁺B cells((9.10±3.32)%)and percentage of CD3^-CD16⁺/56⁺natural killer(NK)cells((17.56±9.28)%)one day before the first cycle of chemotherapy were lower than those in control group((44.96±6.34)%,1.97±0.64,(13.93±5.16)%,(20.70±7.55)%)(P<0.05),the percentage of CD3⁺CD8⁺T cells((26.58±8.29)%)was higher than that in control group((21.94±7.88)%)(P<0.05),and there was no significant difference in the percentage of CD3⁺T cells between colorectal cancer group((71.79±9.17)%)and control group((70.90±8.37)%)(P>0.05).In colorectal cancer group,the percentages of CD3⁺CD4⁺T cells((42.31±8.13)%,(43.31±8.13)%)and the ratios of CD3⁺CD4⁺/CD3⁺CD8⁺T cells(1.67±0.69,1.76±0.64)one day before the third and fifth cycles of chemotherapy were higher than those one day before the first cycle of chemotherapy(P<0.05),the percentage of CD19⁺B cells was lower one day before the third cycle((8.36±3.58)%)and one day before the fifth cycle of chemotherapy((8.18±2.29)%)than that one day before the first cycle of chemotherapy(P<0.05),and there were no significant differences in the percentages of CD3⁺T cells((71.86±10.71)%,(72.56±11.45)%),CD3⁺CD8⁺T cells((28.22±11.82)%,(27.46±10.57)%)and CD3^-CD16⁺/56⁺NK cells((19.05±10.13)%,(18.63±11.66)%)one day before the third and fifth cycles of chemotherapy compared with those one day before the first cycle of chemotherapy(P>0.05).Conclusion Immune function decreases in patients with colorectal cancer after operation.Oxaliplatin plus capecitabine adjuvant chemotherapy can enhance the cellular immune function involved by CD3⁺CD4⁺T cells,inhibit humoral immunity associated with CD19⁺B cells,and has no influence on innate immunity involved by CD3^-CD16⁺/56⁺NK cells.